Correction to: A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents

Abstract

The original article has been corrected. The correct order of the list of authors and their affiliations are as follows.

Development of immunoliposomes containing cytotoxic gold payloads against HER2-positive breast cancers

“…5–7 In addition, liposomes – biocompatible hollow vesicles made up of phospholipids – are particularly attractive as delivery vehicles for a variety of drugs due to their amphipathic nature. 7–9 Monoclonal antibodies (mAb) can be engrafted onto the surface of these liposomes to generate delivery vehicles with targeting properties. 10…”

“…Liposomes offer improved pharmacokinetics and higher blood circulation times, providing for better accumulation to the site of the tumor and preventing toxicity in normal tissue. [5][6][7] In addition, liposomesbiocompatible hollow vesicles made up of phospholipidsare particularly attractive as delivery vehicles for a variety of drugs due to their amphipathic nature. [7][8][9] Monoclonal antibodies (mAb) can be engrafted onto the surface of these liposomes to generate delivery vehicles with targeting properties.…”

“…[5][6][7] In addition, liposomesbiocompatible hollow vesicles made up of phospholipidsare particularly attractive as delivery vehicles for a variety of drugs due to their amphipathic nature. [7][8][9] Monoclonal antibodies (mAb) can be engrafted onto the surface of these liposomes to generate delivery vehicles with targeting properties. 10 Studies have found that immunoliposomes encapsulated with conventional anticancer agentsdocetaxel, 10,11 doxorubicin, 12 paclitaxel and rapamycin 13 and engrafted with trastuzumab show efficient drug encapsulation and delivery, longer circulation times and enhanced anti-tumor efficacy in vitro and in vivo against HER2-positive breast cancers relative to free drug, free mAb, the antibody-drug conjugate ado-trastuzumab emtansine, 11 and control liposomes.…”